UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
March 16, 2022
(Date of earliest event reported)
RELIANCE GLOBAL GROUP, INC.
(Exact name of registrant as specified in its charter)
Florida | 001-40020 | 46-3390293 | ||
(State or other jurisdiction of incorporation) | (Commission File Number) | (IRS Employer Identification No.) |
300 Blvd. of the Americas, Suite 105 Lakewood, NJ | 08701 | |
(Address of principal executive offices) | (Zip Code) |
732-380-4600
(Registrant’s telephone number, including area code)
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
☐ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) | |
☐ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) | |
☐ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) | |
☐ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transmission period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Securities registered pursuant to Section 12(b) of the Act:
Title of each class | Trading Symbol(s) | Name of each exchange on which registered | ||
The Capital Market | ||||
The Capital Market |
Item 8.01 Other Information
As previously disclosed, on January 31, 2022, Nasdaq notified the Company that it did not comply with Nasdaq’s shareholder approval requirements set forth in Listing Rule 5635(d) (the “Rule”) in connection with the acquisition of Medigap Healthcare Insurance Company, LLC. The Company responded to Nasdaq’s request for a Compliance Plan, which has been approved by Nasdaq. As a result, Nasdaq has determined to grant the Company an extension to implement the required changes on or before May 10, 2022 to comply with the Company’s proposed Plan to regain compliance. As a result, the Company is confident that it will be able to regain compliance with Nasdaq’s continued listing criteria within the time period specified.
Item 9.01 Financial Statements and Exhibits.
Exhibit No. | Description | |
104 | Cover Page Interactive Data File (embedded within the Inline XBRL document) |
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
RELIANCE GLOBAL GROUP, INC. | ||
Dated: March 17, 2022 | By: | /s/ Ezra Beyman |
Ezra Beyman Chief Executive Officer |